Natixis Advisors LLC Buys 9,784 Shares of Stryker Corporation $SYK

Natixis Advisors LLC boosted its stake in Stryker Corporation (NYSE:SYK) by 4.6% during the 3rd quarter, Holdings Channel reports. The firm owned 222,332 shares of the medical technology company’s stock after buying an additional 9,784 shares during the quarter. Natixis Advisors LLC’s holdings in Stryker were worth $82,189,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Norges Bank purchased a new stake in shares of Stryker during the 2nd quarter worth approximately $1,882,173,000. Alliancebernstein L.P. raised its position in Stryker by 307.6% during the second quarter. Alliancebernstein L.P. now owns 5,596,508 shares of the medical technology company’s stock valued at $2,214,146,000 after purchasing an additional 4,223,366 shares during the period. Corient Private Wealth LLC lifted its stake in shares of Stryker by 104.4% in the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after purchasing an additional 1,146,998 shares during the last quarter. Strive Asset Management LLC purchased a new position in Stryker during the third quarter worth $227,389,000. Finally, ABN AMRO Bank N.V. bought a new stake in shares of Stryker in the 2nd quarter worth about $191,047,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on SYK shares. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Stryker in a research note on Monday, December 22nd. Truist Financial dropped their target price on Stryker from $400.00 to $392.00 and set a “hold” rating for the company in a research report on Thursday, December 18th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $435.00 price target on shares of Stryker in a report on Friday, November 14th. Robert W. Baird set a $437.00 price objective on Stryker in a research report on Friday, January 30th. Finally, BTIG Research increased their target price on Stryker from $410.00 to $412.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Fourteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $428.61.

Stryker Stock Performance

Stryker stock opened at $364.11 on Monday. The company has a 50 day moving average price of $365.45 and a 200-day moving average price of $368.84. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $404.87. The company has a market capitalization of $139.34 billion, a PE ratio of 43.35, a P/E/G ratio of 2.13 and a beta of 0.85.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.40 by $0.07. The company had revenue of $7.17 billion for the quarter, compared to analysts’ expectations of $7.12 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.Stryker’s revenue was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $4.01 earnings per share. As a group, equities analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be paid a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker’s dividend payout ratio is 41.90%.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares in the company, valued at $891,814,566.52. This represents a 9.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.20% of the stock is currently owned by insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.